JP2019526612A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019526612A5 JP2019526612A5 JP2019513926A JP2019513926A JP2019526612A5 JP 2019526612 A5 JP2019526612 A5 JP 2019526612A5 JP 2019513926 A JP2019513926 A JP 2019513926A JP 2019513926 A JP2019513926 A JP 2019513926A JP 2019526612 A5 JP2019526612 A5 JP 2019526612A5
- Authority
- JP
- Japan
- Prior art keywords
- estradiol
- acid
- combination
- composition according
- dementia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims description 99
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 claims description 54
- 229960005309 Estradiol Drugs 0.000 claims description 49
- 235000019416 cholic acid Nutrition 0.000 claims description 35
- BHQCQFFYRZLCQQ-OELDTZBJSA-N Cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 claims description 33
- 239000004380 Cholic acid Substances 0.000 claims description 33
- 229960002471 cholic acid Drugs 0.000 claims description 33
- 235000008696 isoflavones Nutrition 0.000 claims description 26
- 229930012948 isoflavones Natural products 0.000 claims description 26
- 206010012289 Dementia Diseases 0.000 claims description 25
- 239000003795 chemical substances by application Substances 0.000 claims description 23
- 150000002159 estradiols Chemical class 0.000 claims description 20
- 239000000651 prodrug Substances 0.000 claims description 20
- 229940002612 prodrugs Drugs 0.000 claims description 20
- GOMNOOKGLZYEJT-UHFFFAOYSA-N isoflavone Chemical compound C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 GOMNOOKGLZYEJT-UHFFFAOYSA-N 0.000 claims description 18
- 150000003839 salts Chemical class 0.000 claims description 16
- 239000011780 sodium chloride Substances 0.000 claims description 16
- 239000002253 acid Substances 0.000 claims description 15
- ZQSIJRDFPHDXIC-UHFFFAOYSA-N Daidzein Chemical compound C1=CC(O)=CC=C1C1=COC2=CC(O)=CC=C2C1=O ZQSIJRDFPHDXIC-UHFFFAOYSA-N 0.000 claims description 12
- DXYUAIFZCFRPTH-UHFFFAOYSA-N Glycitein Chemical compound C1=C(O)C(OC)=CC(C2=O)=C1OC=C2C1=CC=C(O)C=C1 DXYUAIFZCFRPTH-UHFFFAOYSA-N 0.000 claims description 12
- 239000003814 drug Substances 0.000 claims description 12
- 150000002516 isoflavones Chemical class 0.000 claims description 8
- NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 claims description 6
- 206010001897 Alzheimer's disease Diseases 0.000 claims description 6
- WUADCCWRTIWANL-UHFFFAOYSA-N Biochanin A Chemical compound C1=CC(OC)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O WUADCCWRTIWANL-UHFFFAOYSA-N 0.000 claims description 6
- 229960001091 Chenodeoxycholic Acid Drugs 0.000 claims description 6
- RUDATBOHQWOJDD-BSWAIDMHSA-N Chenodeoxycholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-BSWAIDMHSA-N 0.000 claims description 6
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 claims description 6
- 201000010450 Creutzfeldt-Jakob disease Diseases 0.000 claims description 6
- KXGVEGMKQFWNSR-LLQZFEROSA-N Deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 claims description 6
- HKQYGTCOTHHOMP-UHFFFAOYSA-N Formononetin Chemical compound C1=CC(OC)=CC=C1C1=COC2=CC(O)=CC=C2C1=O HKQYGTCOTHHOMP-UHFFFAOYSA-N 0.000 claims description 6
- ASUTZQLVASHGKV-JDFRZJQESA-N Galantamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 claims description 6
- 229940099347 Glycocholic Acid Drugs 0.000 claims description 6
- 108010007979 Glycocholic Acid Proteins 0.000 claims description 6
- RFDAIACWWDREDC-FRVQLJSFSA-N Glycocholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 RFDAIACWWDREDC-FRVQLJSFSA-N 0.000 claims description 6
- 208000006264 Korsakoff Syndrome Diseases 0.000 claims description 6
- 201000002832 Lewy body dementia Diseases 0.000 claims description 6
- SMEROWZSTRWXGI-HVATVPOCSA-N Lithocholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 SMEROWZSTRWXGI-HVATVPOCSA-N 0.000 claims description 6
- BHTRKEVKTKCXOH-LBSADWJPSA-N Tauroursodeoxycholic acid Chemical group C([C@H]1C[C@@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)CC1 BHTRKEVKTKCXOH-LBSADWJPSA-N 0.000 claims description 6
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 claims description 6
- RUDATBOHQWOJDD-UZVSRGJWSA-N Ursodeoxycholic acid Chemical compound C([C@H]1C[C@@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-UZVSRGJWSA-N 0.000 claims description 6
- 229960001661 Ursodiol Drugs 0.000 claims description 6
- 229960003473 androstanolone Drugs 0.000 claims description 6
- 229950001904 chenodiol Drugs 0.000 claims description 6
- 239000000544 cholinesterase inhibitor Substances 0.000 claims description 6
- 235000007240 daidzein Nutrition 0.000 claims description 6
- KYQZWONCHDNPDP-QNDFHXLGSA-N daidzein 7-O-β-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 KYQZWONCHDNPDP-QNDFHXLGSA-N 0.000 claims description 6
- 229960003964 deoxycholic acid Drugs 0.000 claims description 6
- 229940079593 drugs Drugs 0.000 claims description 6
- 201000011240 frontotemporal dementia Diseases 0.000 claims description 6
- 235000008466 glycitein Nutrition 0.000 claims description 6
- 201000003077 normal pressure hydrocephalus Diseases 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- JAJWGJBVLPIOOH-IZYKLYLVSA-M sodium taurocholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 JAJWGJBVLPIOOH-IZYKLYLVSA-M 0.000 claims description 6
- 150000003515 testosterones Chemical class 0.000 claims description 6
- 229940115889 ursodeoxycholic acid Drugs 0.000 claims description 6
- 201000004810 vascular dementia Diseases 0.000 claims description 6
- QADHLRWLCPCEKT-LOVVWNRFSA-N 5-Androstenediol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC=C21 QADHLRWLCPCEKT-LOVVWNRFSA-N 0.000 claims description 5
- AEMFNILZOJDQLW-QAGGRKNESA-N Androstenedione Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 AEMFNILZOJDQLW-QAGGRKNESA-N 0.000 claims description 5
- 229960005471 Androstenedione Drugs 0.000 claims description 5
- 206010061536 Parkinson's disease Diseases 0.000 claims description 5
- 229950009148 androstenediol Drugs 0.000 claims description 5
- 229940021182 non-steroidal anti-inflammatory drugs Drugs 0.000 claims description 5
- 206010067889 Dementia with Lewy body Diseases 0.000 claims description 4
- 102100002615 TKT Human genes 0.000 claims description 4
- 101700044444 TKT Proteins 0.000 claims description 4
- 201000008485 Wernicke-Korsakoff syndrome Diseases 0.000 claims description 4
- 239000000546 pharmaceutic aid Substances 0.000 claims description 4
- UYIFTLBWAOGQBI-BZDYCCQFSA-N Benzhormovarine Chemical compound C([C@@H]1[C@@H](C2=CC=3)CC[C@]4([C@H]1CC[C@@H]4O)C)CC2=CC=3OC(=O)C1=CC=CC=C1 UYIFTLBWAOGQBI-BZDYCCQFSA-N 0.000 claims description 3
- ADEBPBSSDYVVLD-UHFFFAOYSA-N Donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 claims description 3
- 229950002007 ESTRADIOL BENZOATE Drugs 0.000 claims description 3
- XSVMFMHYUFZWBK-NSHDSACASA-N EXELON Chemical compound CCN(C)C(=O)OC1=CC=CC([C@H](C)N(C)C)=C1 XSVMFMHYUFZWBK-NSHDSACASA-N 0.000 claims description 3
- 229960003851 Estradiol Hemihydrate Drugs 0.000 claims description 3
- 229960003575 Estradiol acetate Drugs 0.000 claims description 3
- RSEPBGGWRJCQGY-RBRWEJTLSA-N Estradiol valerate Chemical compound C1CC2=CC(O)=CC=C2[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CCCC)[C@@]1(C)CC2 RSEPBGGWRJCQGY-RBRWEJTLSA-N 0.000 claims description 3
- BFPYWIDHMRZLRN-SLHNCBLASA-N Etivex Chemical group OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 claims description 3
- 229960003980 Galantamine Drugs 0.000 claims description 3
- 229940045109 Genistein Drugs 0.000 claims description 3
- ZCOLJUOHXJRHDI-CMWLGVBASA-N Genistin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 ZCOLJUOHXJRHDI-CMWLGVBASA-N 0.000 claims description 3
- BUGYDGFZZOZRHP-UHFFFAOYSA-N Memantine Chemical compound C1C(C2)CC3(C)CC1(C)CC2(N)C3 BUGYDGFZZOZRHP-UHFFFAOYSA-N 0.000 claims description 3
- 229960003604 Testosterone Drugs 0.000 claims description 3
- FHXBMXJMKMWVRG-SLHNCBLASA-N [(8R,9S,13S,14S,17S)-17-hydroxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-3-yl] acetate Chemical compound C1C[C@]2(C)[C@@H](O)CC[C@H]2[C@@H]2CCC3=CC(OC(=O)C)=CC=C3[C@H]21 FHXBMXJMKMWVRG-SLHNCBLASA-N 0.000 claims description 3
- 229960001138 acetylsalicylic acid Drugs 0.000 claims description 3
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims description 3
- 229960003530 donepezil Drugs 0.000 claims description 3
- ADFCQWZHKCXPAJ-GFCCVEGCSA-N equol Chemical compound C1=CC(O)=CC=C1[C@@H]1CC2=CC=C(O)C=C2OC1 ADFCQWZHKCXPAJ-GFCCVEGCSA-N 0.000 claims description 3
- 235000019126 equol Nutrition 0.000 claims description 3
- 229960004766 estradiol valerate Drugs 0.000 claims description 3
- 229960002568 ethinylestradiol Drugs 0.000 claims description 3
- TZBJGXHYKVUXJN-UHFFFAOYSA-N genistein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O TZBJGXHYKVUXJN-UHFFFAOYSA-N 0.000 claims description 3
- 235000006539 genistein Nutrition 0.000 claims description 3
- 229960004640 memantine Drugs 0.000 claims description 3
- 229960004136 rivastigmine Drugs 0.000 claims description 3
- 238000001990 intravenous administration Methods 0.000 claims description 2
- 238000007920 subcutaneous administration Methods 0.000 claims description 2
- 238000002560 therapeutic procedure Methods 0.000 claims description 2
- 201000010099 disease Diseases 0.000 claims 3
- BHTRKEVKTKCXOH-VGGMBIBKSA-N 2-[4-[(3R,5S,7S,8R,9S,10S,13R,14S)-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoylamino]ethanesulfonic acid Chemical group C([C@H]1C[C@@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CCC(C(CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)CC1 BHTRKEVKTKCXOH-VGGMBIBKSA-N 0.000 claims 2
- KQMVAGISDHMXJJ-UHFFFAOYSA-N Prunetin Chemical compound C=1C(OC)=CC(O)=C(C2=O)C=1OC=C2C1=CC=C(O)C=C1 KQMVAGISDHMXJJ-UHFFFAOYSA-N 0.000 claims 2
- BHTRKEVKTKCXOH-AYSJQVDDSA-N taurochenodeoxycholic acid Chemical compound C([C@H]1C[C@@H]2O)[C@H](O)CC[C@]1(C)C1C2C2CC[C@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)CC1 BHTRKEVKTKCXOH-AYSJQVDDSA-N 0.000 claims 2
- RAJWOBJTTGJROA-RNQTWYFASA-N Androstanedione Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC21 RAJWOBJTTGJROA-RNQTWYFASA-N 0.000 claims 1
- ZRPLANDPDWYOMZ-UHFFFAOYSA-N Cypionic acid Chemical compound OC(=O)CCC1CCCC1 ZRPLANDPDWYOMZ-UHFFFAOYSA-N 0.000 claims 1
- 210000000664 Rectum Anatomy 0.000 claims 1
- 210000001215 Vagina Anatomy 0.000 claims 1
- 230000001058 adult Effects 0.000 claims 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims 1
- 201000001971 Huntington's disease Diseases 0.000 description 4
- -1 irilon Chemical compound 0.000 description 4
- MMPVAPMCVABQPS-UHFFFAOYSA-N luteone Chemical compound O=C1C2=C(O)C(CC=C(C)C)=C(O)C=C2OC=C1C1=CC=C(O)C=C1O MMPVAPMCVABQPS-UHFFFAOYSA-N 0.000 description 4
- 208000009829 Lewy Body Disease Diseases 0.000 description 2
- 239000002812 cholic acid derivative Substances 0.000 description 2
- 150000001842 cholic acids Chemical class 0.000 description 2
- 229960005416 estradiol cypionate Drugs 0.000 description 2
- 150000002338 glycosides Chemical class 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000006011 modification reaction Methods 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662393140P | 2016-09-12 | 2016-09-12 | |
| US62/393,140 | 2016-09-12 | ||
| US201762507531P | 2017-05-17 | 2017-05-17 | |
| US62/507,531 | 2017-05-17 | ||
| PCT/US2017/050653 WO2018049141A1 (fr) | 2016-09-12 | 2017-09-08 | Compositions destinées au traitement de la démence |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019526612A JP2019526612A (ja) | 2019-09-19 |
| JP2019526612A5 true JP2019526612A5 (fr) | 2020-10-08 |
Family
ID=59901615
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019513926A Pending JP2019526612A (ja) | 2016-09-12 | 2017-09-08 | 認知症を治療するための組成物 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US10300077B2 (fr) |
| EP (1) | EP3509639A1 (fr) |
| JP (1) | JP2019526612A (fr) |
| KR (1) | KR20190072521A (fr) |
| CN (2) | CN110177572A (fr) |
| AU (1) | AU2017322332A1 (fr) |
| BR (1) | BR112019004540A2 (fr) |
| CA (1) | CA3036511A1 (fr) |
| IL (1) | IL265255A (fr) |
| MX (1) | MX2019002673A (fr) |
| PH (1) | PH12019500479A1 (fr) |
| WO (1) | WO2018049141A1 (fr) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL237739B1 (pl) | 2018-06-06 | 2021-05-17 | Univ Gdanski | Genisteina do zastosowania do leczenia choroby Alzheimera |
| EA202193111A1 (ru) | 2019-05-14 | 2022-02-10 | Тайм, Инк. | Композиции и способы для лечения рака |
| US10905698B1 (en) * | 2020-05-14 | 2021-02-02 | Tyme, Inc. | Methods of treating SARS-COV-2 infections |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH03161442A (ja) | 1989-11-21 | 1991-07-11 | Chiyouseidou Seiyaku Kk | コール酸又はそのナトリウム塩からなる脳代謝改善剤 |
| JPH06100466A (ja) * | 1992-02-14 | 1994-04-12 | Tsumura & Co | ストレス性脳神経細胞器質障害防御剤 |
| US5733926A (en) | 1996-12-13 | 1998-03-31 | Gorbach; Sherwood L. | Isoflavonoids for treatment and prevention of alzheimer dementia and reduced cognitive functions |
| US5952374A (en) * | 1997-09-29 | 1999-09-14 | Protein Technologies International, Inc. | Method for inhibiting the development of Alzheimer's disease and related dementias- and for preserving cognitive function |
| US20040044080A1 (en) * | 1997-10-28 | 2004-03-04 | Place Virgil A. | Treatment of dyspareunia with topically administered nitroglycerin formulations |
| JP4609875B2 (ja) * | 2001-07-31 | 2011-01-12 | 有限会社大長企画 | 健康食品 |
| US7338971B2 (en) | 2001-08-30 | 2008-03-04 | El-Naggar Mawaheb M | Treatment of inflammatory, cancer, and thrombosis disorders |
| JP5384777B2 (ja) * | 2001-12-18 | 2014-01-08 | 有限会社大長企画 | 強筋肉剤、抗炎症剤 |
| KR101358078B1 (ko) * | 2004-11-01 | 2014-02-06 | 주식회사 유스팜인터내셔널 | 근위축성 측삭 경화증의 신경퇴행을 감소시키기 위한 방법및 조성물 |
| US20090123571A1 (en) | 2005-03-25 | 2009-05-14 | Alan Meehan | Method of treating men with testosterone supplement and 5alpha-reductase inhibitor |
| WO2007016766A1 (fr) * | 2005-08-05 | 2007-02-15 | Nuvo Research Inc. | Formulation pour l'administration transdermique de medicaments |
| CA2623839C (fr) * | 2005-09-26 | 2013-12-17 | The Regents Of The University Of California | Therapie par estriol pour maladie des troubles auto-immuns et neurodegeneratifs |
| CA2659905A1 (fr) * | 2006-08-02 | 2008-02-07 | Roberta Diaz Brinton | Formulations phyto-oestrogeniques pour soulager ou prevenir des maladies neurodegeneratives |
| NZ595630A (en) * | 2009-04-09 | 2013-04-26 | Amicus Therapeutics Inc | Methods for preventing and/or treating degenerative disorders of the central nervous system |
| CN102397550B (zh) | 2011-08-30 | 2013-05-08 | 广东医学院 | 一组由阿司匹林与雌激素组成的防治骨质疏松症的药物组合物 |
| EP2781214A1 (fr) | 2013-03-22 | 2014-09-24 | Chemo Research, S.L. | Formulation de calcium amorphe L-5-méthyltétrahydrofolate (L-5-MTHF-Ca) |
| US9872865B2 (en) * | 2013-03-24 | 2018-01-23 | Amylyx Pharmaceuticals Inc. | Compositions for improving cell viability and methods of use thereof |
| US20160120941A1 (en) * | 2013-05-31 | 2016-05-05 | Regeneron Pharmaceuticals, Inc. | Methods of using il-1 antagonists to treat alzheimer's disease |
-
2017
- 2017-09-08 CA CA3036511A patent/CA3036511A1/fr not_active Abandoned
- 2017-09-08 MX MX2019002673A patent/MX2019002673A/es unknown
- 2017-09-08 JP JP2019513926A patent/JP2019526612A/ja active Pending
- 2017-09-08 EP EP17768935.3A patent/EP3509639A1/fr active Pending
- 2017-09-08 CN CN201780055706.XA patent/CN110177572A/zh active Pending
- 2017-09-08 BR BR112019004540A patent/BR112019004540A2/pt not_active IP Right Cessation
- 2017-09-08 WO PCT/US2017/050653 patent/WO2018049141A1/fr unknown
- 2017-09-08 AU AU2017322332A patent/AU2017322332A1/en not_active Abandoned
- 2017-09-08 KR KR1020197010138A patent/KR20190072521A/ko not_active Application Discontinuation
- 2017-09-08 US US15/699,364 patent/US10300077B2/en active Active
- 2017-09-08 CN CN202210417996.0A patent/CN114796236A/zh active Pending
-
2019
- 2019-03-05 PH PH12019500479A patent/PH12019500479A1/en unknown
- 2019-03-10 IL IL265255A patent/IL265255A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2342145C2 (ru) | Селективные модуляторы рецептора эстрогена в комбинации с эстрогенами | |
| JP2019526612A5 (fr) | ||
| US20080021003A1 (en) | Extended step-down estrogen regimen | |
| WO2014071449A1 (fr) | Stéroïdes neuroactifs et leur utilisation pour faciliter la neuroprotection | |
| WO2018049141A4 (fr) | Compositions destinées au traitement de la démence | |
| JP2016527307A5 (fr) | ||
| NO20065657L (no) | Filmformet ostriol-inneholdende medikament for oral administrasjon | |
| JP2019509309A5 (fr) | ||
| WO2004080414A2 (fr) | Composition et procede de traitement d'inflammations par reduction des proteines c-reactives | |
| ES2320662T3 (es) | Hormonoterapia restitutiva y tratamiento para la depresion con dienogest. | |
| JP6940279B2 (ja) | 注腸剤 | |
| Abbas et al. | The protective and therapeutic effects of 5-androstene3β, 17β-diol (ADIOL) in abdominal post-operative adhesions in rat: Suppressing TLR4/NFκB/HMGB1/TGF1 β/α SMA pathway | |
| JP2022173353A (ja) | 注腸剤 | |
| Von Schoultz | Clinical efficacy and safety of combined estradiol valerate and dienogest: a new no-bleed treatment | |
| AU2006226381B2 (en) | Use of macrolides for treating intestinal inflammation | |
| JP5985475B2 (ja) | 新規医薬組成物 | |
| RU2002124602A (ru) | Композиция для мужской контрацепции, включающая норэтистерон | |
| JP2005532336A5 (fr) | ||
| TW200730180A (en) | Therapeutic uses of steroidal compounds | |
| JP4233766B2 (ja) | 高い薬用量でのジエノゲストの使用 | |
| WO2020261602A1 (fr) | Composition pharmaceutique | |
| JP2007084514A (ja) | 炎症性腸疾患用グリチルリチン製剤 | |
| KR20220037979A (ko) | 수가용화된 담즙산을 포함하는 패혈증, 급성 폐손상 질환, 또는 급성 호흡곤란증후군의 예방 또는 치료용 약학 조성물 | |
| Zylicz | The systemic effects of local infiltrations with corticosteroids. Implications for palliative care? | |
| RU2002117297A (ru) | 3-метиленстероидные производные |